News

The latest from Velocity Clinical Research

Velocity Announces New MASH CARE Council

November 2, 2023

Velocity is proud to announce the MASH Council to Accelerate Research Excellence (CARE). Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, the MASH CARE Council will help drive world-class operational, recruitment, and trial conduct oversight for the 20+ … Read more

Paul Evans Named CEO of the Year by Business North Carolina

November 1, 2023

Paul Evans was recently named CEO of the Year in the Middle Market Division by Business North Carolina! He, along with his fellow awardees in the Enterprise and Growth categories, were celebrated last month at the annual CEO Summit. Since moving to North Carolina … Read more

Kris Kowdley, MD, Velocity PI, Lead Author of Article Published in The Lancet Gastroenterology & Hepatology

October 27, 2023
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, Principal Investigator at Velocity Lead Author, Article Published in The Lancet Gastroenterology & Hepatology

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was the lead author of an article recently published in The Lancet Gastroenterology & Hepatology. Dr. Kowdley and team conducted a Phase 2 trial investigating the efficacy of rusfertide in treating HFE-related haemochromatosis (an inherited iron overload … Read more

Velocity Aggressively Expands MASH/MASLD Capabilities with Latest Site Acquisitions

October 25, 2023
Velocity Expands MASH/MASLD Capabilities With New Sites in Seattle, WA, and Waco, TX

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD … Read more

Julio Rosenstock, MD, FACE, Presents Promising Data on Oral Semaglutide’s Effect on HbA1c for Adults with Prediabetes

October 24, 2023
Julio Rosenstock, MD, FACE, presents promising data on oral semaglutide’s effect on HbA1c for adults with prediabetes

Julio Rosenstock, MD, FACE, Principal Investigator at Velocity and the leader of the Diabetes and Obesity CARE Council, unveiled data suggesting a potential breakthrough for adults with prediabetes. When administered oral semaglutide, trial participants achieved normoglycemia at 68 weeks. Dr. Rosenstock commented, “Those people … Read more

Velocity Eczema Trials Enhance Patient Quality of Life

October 20, 2023

Shiva Muthiah, Director of UK Operations for Velocity, smiles as she recalls the triumph of a teenage patient battling a painful eczema skin condition. “He used to wear long sleeves and other clothing designed to hide the marks on his skin, but almost immediately … Read more

Velocity Launches Cardiology Council to Accelerate Research Excellence (CARE)

October 12, 2023

Velocity is proud to unveil another groundbreaking initiative: the Cardiology Council to Accelerate Research Excellence (CARE). Headed by William Cromwell, MD, FAHA, FNLA and Steven Martin, MD, FACC, the Cardiology CARE Council will support strategic partnerships with Sponsors and CROs, backed by Velocity’s extensive … Read more

Velocity Wins the 2023 SCRS Excellence in Patient Centricity Award

October 9, 2023

Velocity has won the 2023 SCRS Excellence in Patient Centricity Award. The award was presented to the Velocity team at the 2023 Global Site Solutions Summit in Hollywood, FL. This award recognizes an organization that has “proven its commitment to effective patient engagement by … Read more

Velocity Opens Three UK Greenfield Clinical Research Sites

October 4, 2023

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. market.  The sites launch at a time when clinical trial activity in the U.K. has … Read more

Six Velocity Principal Investigators Co-Author Article Published in Nature Medicine

September 28, 2023
A quote from the article.

Six Velocity Principal Investigators coauthored an article recently published in Nature Medicine. The article covers the results of a Phase 2/3 trial of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Beyond yielding promising results, the trial has … Read more

‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

September 21, 2023
‘New Era’ for Alzheimer’s Treatments Spur Researcher Optimism

After battling on the frontline for many years against an aggressive and elusive opponent, Michael Hemphill, MD and the Velocity team in Savannah, GA, believe we’ve entered an exciting “new era” in the fight against Alzheimer’s disease and dementia. Velocity conducts clinical trials related to … Read more

Velocity Syracuse Team Advances Important Alzheimer’s Trials 

September 21, 2023
Velocity Syracuse Team Advances Important Alzheimer’s Trials

Alzheimer’s is currently ranked as the seventh leading cause of death in the United States and is the most common cause of dementia among older adults.  Alzheimer’s disease, a cruel and pernicious affliction, is a brain disorder that slowly destroys memory, thinking skills, and … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.